Skip to content

The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy

A Pilot Study to Assess the Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00774501
Enrollment
10
Registered
2008-10-17
Start date
2008-10-31
Completion date
2016-02-29
Last updated
2016-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Keywords

Anesthesia, suspended ventilation

Brief summary

Liver tumors are hard to treat with radiation because the liver moves every time you breathe. The purpose of this study is to test a new and possibly more accurate way of treating liver tumors. When a person is asleep under anesthesia, it is safe to stop breathing motion for a while. The liver will stop moving and radiation can be given to a liver tumor. The study is being done to see if radiation can be given to liver tumors safely and accurately in this way.

Interventions

PROCEDUREimage guidance with general anesthesia and suspended ventilation during treatment delivery

All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC. Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational. The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery.

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient eligible to receive external beam intensity modulated radiotherapy for liver cancer * Age:21\<80 * KPS \> or = to 80 * Able to tolerate immobilization cradle positioning * Able to give informed consent * Histologically confirmed diagnosis of solid tumor malignancy * Liver metastases visualized on CT imaging (obtained within approximately 6 months from enrollment). * Target lesion ≤ or = to 8 cm in maximal diameter * In the case of multiple liver metastases, only one lesion will be targeted per treatment session. Typically the target lesion will be the lesion which is progressing or the cause of symptoms. The target lesion will be picked in consultation with the referring physician.

Exclusion criteria

* Lymphoid primary histology (lymphoma/leukemia) * Single metastasis in an operable patient. Operable lesions will only be considered for enrollment in the protocol if the patient refuses resection of the metastasis. * Target lesion \> 8 cm in maximal diameter * Cirrhosis of the liver (Child's C) * Liver function enzymes (AST, ALT) \> 3x normal , obtained within 1 month of treatment. * \< 500 cc uninvolved liver * Unable to tolerate intravenous CT contrast * Serum Hemoglobin \< 9.0 (obtained within 1 month of treatment) * Presence of untreated brain metastases * Severe pulmonary disease (O2 dependent, unable to walk a flight of stairs) * Unstable cardiac status * Unstable angina * Significant abnormal 12 lead EKG (non sinus arrhythmia or ischemia unsuitable for general anesthesia) * Congestive Heart Failure * Abnormal kidney function (serum creatinine \> 1.5) obtained within 1 month of treatment * Platelet count \<70.000. (obtained within 1 month of treatment). * INR \> 2.0 (obtained within 1 month of treatment) * Marker seed placement not possible * Implanted defibrillator/pacemaker * Evidence of increased intracranial pressure * Significant ascites * Morbid Obesity * Pregnancy

Design outcomes

Primary

MeasureTime frame
To assess safety & feasibility of single dose image-guided intensity modulated radio (IG-IMRT) using gen anesthesia with apneic oxygenation & controlled ventilation to temp suspend respiratory motion for tx of mets liver disease during localization & tx.conclusion of study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026